Evidence that the multiflorine-derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α2 -adrenoceptors in mice.

Zsuzsanna LehnerKarin StadlbauerBarbara BrunmairImmanuel AdorjanMiroslav GenovAlexandra Kautzky-Willer Thomas SchererMika ScheininLeonhardt BauerClemens Fürnsinn

Published in: Diabetes, obesity & metabolism (2019)

Our findings suggest that 55P0251 and related multiflorine derivatives are to be categorized as α2 -adrenoceptor antagonists with potential to lower blood glucose by blocking α2A -adrenoceptors on pancreatic β cells.

Keyphrases

blood glucose
induced apoptosis
glycemic control
blood pressure
cell cycle arrest
molecular docking
high fat diet induced
type diabetes
endoplasmic reticulum stress
oxidative stress
insulin resistance
risk assessment
skeletal muscle
climate change